Diabetes treatments and cancer risk: The importance of considering aspects of drug exposure

The Lancet Diabetes and Endocrinology

Volumn 1, Issue 2, 2013, Pages 132-139

  Walker, Jeremy J ^a   Johnson, Jeffrey A ^b   Wild, Sarah H ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; BILE ACID SEQUESTRANT; BROMOCRIPTINE; COLESEVELAM; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; EXENDIN 4; GLIBENCLAMIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HYPOCHOLESTEROLEMIC AGENT; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT;

CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; COLONOSCOPY; DIABETES MELLITUS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; DRUG EXPOSURE; DRUG MECHANISM; HUMAN; NEOPLASM; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SENSITIVITY ANALYSIS; TREATMENT DURATION; NEOPLASMS; OCCUPATIONAL EXPOSURE; ONSET AGE; RISK FACTOR; STATISTICS AND NUMERICAL DATA;

AGE OF ONSET; DIABETES MELLITUS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPOGLYCEMIC AGENTS; NEOPLASMS; OCCUPATIONAL EXPOSURE; RISK FACTORS;

EID: 84884500518     PISSN: 22138587     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-8587(13)70028-7     Document Type: Review

References (69)

1. Diabetes Fact Sheet no 312 (September, 2012) WHO, (accessed April 2, 2013). http://www.who.int/mediacentre/factsheets/fs312/en/index.html.
2. Larsson SC, Mantzoros CS, Wolk A Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 2007, 121:856-862.
3. Friberg E, Orsini N, Mantzoros CS, Wolk A Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia 2007, 50:1365-1374.
4. Bonovas S, Filioussi K, Tsantes A Diabetes mellitus and risk of prostate cancer: a meta analysis. Diabetologia 2004, 47:1071-1078.
5. Kasper JS, Giovannucci E A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006, 15:2056-2062.
6. El-Serag HB, Hampel H, Javadi F The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006, 4:369-380.
7. Wang P, Kang D, Cao W, Wang Y, Liu Z Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis. Diabetes Metab Res Rev 2012, 28:109-122.
8. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 2005, 92:2076-2083.
9. Ben Q, Xu M, Ning X, et al. Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies. Eur J Cancer 2011, 47:1928-1937.
10. Larsson SC, Orsini N, Brismar K, Wolk A Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia 2006, 49:2819-2823.
11. Larsson SC, Orsini N, Wolk A Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 2005, 97:1679-1687.
12. Deng L, Gui Z, Zhao L, Wang J, Shen L Diabetes mellitus and the incidence of colorectal cancer: an updated systematic review and meta-analysis. Dig Dis Sci 2012, 57:1576-1585.
13. Erbach M, Mehnert H, Schnell O Diabetes and the risk for colorectal cancer. J Diabetes Complications 2012, 26:50-55.
14. Sun L, Yu S Diabetes mellitus is an independent risk factor for colorectal cancer. Dig Dis Sci 2012, 57:1586-1597.
15. Larsson SC, Wolk A Diabetes mellitus and incidence of kidney cancer: a meta-analysis of cohort studies. Diabetologia 2011, 54:1013-1018.
16. Mitri J, Castillo J, Pittas AG Diabetes and risk of non-Hodgkins lymphoma: a meta-analysis of observational studies. Diabetes Care 2008, 31:2391-2397.
17. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R Diabetes and cancer. Endoc Relat Cancer 2009, 16:1103-1123.
18. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care 2010, 33:1674-1685.
19. Nicolucci A Epidemiological aspects of neoplasms in diabetes. Acta Diabetol 2010, 47:87-95.
20. Onitilo AA, Engel JM, Glurich I, Stankowski RV, Williams GM, Doi SA Diabetes and cancer II: role of diabetes drugs and influence of shared risk factors. Cancer Causes Control 2012, 23:991-1008.
21. Dejgaard A, Lynggaard H, Rastam J, Krogsgaard Thomsen M No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis. Diabetologia 2009, 52:2507-2512.
22. Home PD, Lagarenne P Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 2009, 52:2499-2506.
23. Pollak M, Russell-Jones D Insulin analogues and cancer risk: cause for concern or cause celebre?. Int J Clin Pract 2010, 64:628-636.
24. Chowdhury TA Diabetes and cancer. QJM 2010, 103:905-915.
25. Currie CJ, Poole CD, Gale EAM The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009, 52:1766-1777.
26. Bowker SL, Majumdar SR, Veugelers P, Johnson JA Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006, 29:254-258.
27. Currie CJ, Poole CD, Jenkins-Jones S, Gale EAM, Johnson JA, Morgan CL Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care 2012, 35:299-304.
28. Suissa S, Azoulay L Metformin and the risk of cancer. Diabetes Care 2012, 35:2665-2673.
29. Govindarajan R, Ratnasinghe L, Simmons DL, et al. Thiazolidinediones and the risk of lung, prostate and colon cancer in patients with diabetes. J Clin Oncol 2007, 25:1476-1481.
30. Ramos-Nino ME, MacLean CD, Littenberg B Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System. BMC Med 2007, 5:17.
31. Monami M, Lamanna C, Marchionni N, Mannucci E Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials. Diabetes Care 2008, 31:1455-1460.
32. Monami M, Lamanna C, Balzi D, Marchionni N, Mannucci E Sulphonylureas and cancer: a case control study. Acta Diabetol 2009, 46:279-284.
33. Tseng C-H Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan. Diabetologia 2011, 54:2009-2015.
34. Knudsen LB, Madsen LW, Andersen S, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010, 51:1473-1486.
35. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1 based therapies. Gastroenterology 2011, 141:150-156.
36. Brubaker PL Minireview: update on incretin biology: focus on glucagon-like peptide-1. Endocrinology 2010, 151:1984-1989.
37. Butler PC, Matveyenko AV, Dry S, Bushan A, Elashoff R Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire?. Diabetologia 2010, 53:1-6.
38. Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 2010, 33:428-433.
39. Monami M, Dicembrini I, Martelli D, Mannucci E Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin 2011, 27(suppl 3):57-64.
40. Cai L, Cai Y, Lu ZJ, Zhang Y, Liu P The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials. J Clin Pharm Ther 2012, 37:386-398.
41. Bhartia M, Tahrani AA, Barnett AH SGLT-2 inhibitors in development for type 2 diabetes treatment. Rev Diabet Stud 2011, 8:348-354.
42. FDA briefing document: dapagliflozin tablets, 5 and 10 mg. 2011. Report no NDA202293 US Food and Drug Administration, (accessed April 2, 2013). http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM262994.pdf.
43. Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 2008, 31:1479-1484.
44. Ferrara A, Lewis JD, Quesenberry CP, et al. Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care 2011, 34:923-929.
45. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JMM New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009, 32:1620-1625.
46. Koro C, Barrett S, Qizilbash N Cancer risks in thiazolidinedione users compared to other anti diabetic agents. Pharmacoepidemiol Drug Saf 2007, 16:485-492.
47. Jiralerspong S, Palla SL, Giordano SH, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2010, 27:3297-3302.
48. Landman GWD, Kleefstra N, van Hateren KJJ, Groenier KH, Gans ROB, Bilo HJG Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 2010, 33:322-326.
49. Yang X, So WY, Ma RCW, et al. Use of sulphonylurea and cancer in type 2 diabetes-the Hong Kong Diabetes Registry. Diabetes Res Clin Pract 2010, 90:343-351.
50. Azoulay L, Dell'Aniello S, Gagnon B, Pollack M, Suissa S Metformin and the incidence of prostate cancer in patients with type 2 diabetes. Cancer Epidemiol Biomarkers Prev 2011, 20:337-344.
51. Baur DM, Klotsche J, Hamnvik OP, et al. Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort. Metabolism 2011, 60:1363-1371.
52. Bodmer M, Becker C, Meier C, Jick SS, Meier CR Use of metformin and the risk of ovarian cancer: a case-control analysis. Gynecol Oncol 2011, 123:200-204.
53. Bodmer M, Becker C, Meier C, Jick SS, Meier CR Use of antidiabetic agents and the risk of pancreatic cancer: a case-control analysis. Am J Gastroenterol 2012, 107:620-626.
54. Bodmer M, Becker C, Meier C, Jick SS, Meier CR Use of metformin is not associated with a decreased risk of colorectal cancer: a case-control analysis. Cancer Epidemiol Biomarkers Prev 2012, 21:280-286.
55. He X, Esteva FJ, Ensor J, Hortobagyi GN, Lee M-H, Yeung S-CJ Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. AnnOncol 2012, 23:1771-1780.
56. NCI dictionary of cancer terms: pack year US National Cancer Institute, (accessed April 2, 2013). http://www.cancer.gov/dictionary?CdrID=306510.
57. Villines TC, Stanek EJ, Devine PJ, et al. The ARBITER 6-HALTS Trial (arterial biology for the investigation of the treatment effects of reducing cholesterol 6-HDL and LDL treatment strategies in atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol 2010, 55:2721-2726.
58. Bowker SL, Yasui Y, Veugelers P, Johnson JA Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure. Diabetologia 2010, 53:1631-1637.
59. Axelson O, Forastiere F, Frederickson M Assessing dose-response relationships by cumulative exposure in epidemiological studies. Am J Ind Med 2007, 50:217-220.
60. Meira-Machado L, de Una-Alvarez J, Cadarso-Suarez C, Andersen PK Multi-state models for the analysis of time-to-event data. Stat Methods Med Res 2009, 18:195-222.
61. Bowker SL, Richardson K, Marra CA, Johnson JA Risk of breast cancer after onset of type 2 diabetes: evidence of detection bias in postmenopausal women. Diabetes Care 2011, 34:2542-2544.
62. Johnson JA, Bowker SL, Richardson K, Marra CA Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias. Diabetologia 2011, 54:2263-2271.
63. Carstensen B, Witte DR, Friis S Cancer occurrence in Danish diabetic patients: duration and insulin effects. Diabetologia 2012, 55:948-958.
64. Andersson C, Vaag A, Selmer C, et al. Risk of cancer in patients using glucose-lowering agents: a nationwide cohort study of 3·6 million people. BMJ Open 2012, 2:e000433.
65. Lewis JD, Capra AM, Achacoso NS, et al. Medical therapy for diabetes is associated with increased use of lower endoscopy. Pharmacoepidemiol Drug Saf 2007, 16:1195-1202.
66. Mongan J, Mieszczanska HZ, Smith BH, et al. Pioglitazone inhibits platelet function and potentiates the effects of aspirin: a prospective observation study. Thromb Res 2012, 129:760-764.
67. Wood L, Martinez C The General Practice Research Database: role in pharmacovigilance. Drug Saf 2004, 27:871-881.
68. Dregan A, Moller H, Murray-Thomas T, Gulliford MC Validity of cancer diagnosis in a primary care database compared with linked cancer registrations in England. Population-based cohort study. Cancer Epidemiol 2012, 36:425-429.
69. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ Validation and validity of diagnoses in the general practice research database: a systematic review. Br J Clin Pharmacol 2010, 69:4-14.